Healthcare Equipment and Supplies
Company Overview of Intrinsic Therapeutics, Inc.
Intrinsic Therapeutics, Inc., a medical device company, develops therapies for treating disc herniations in the spine for discectomy patients. It offers Barricaid anular prosthesis that enables the direct reconstruction of weakened and ruptured annulus and soft tissues of the spine. The company also offers spinal implants to treat the causes of sciatica and low back pain. It serves surgeons and patients. The company was formerly known as Intrinsic Orthopedics, Inc. and changed its name to Intrinsic Therapeutics, Inc. in January 2003. Intrinsic Therapeutics was founded in 2000 and is based in Woburn, Massachusetts.
30 Commerce Way
Woburn, MA 01801
Founded in 2000
Key Executives for Intrinsic Therapeutics, Inc.
Chief Executive Officer and President
Founder and Executive Director
Vice President of Research & Development
Director of Intellectual Property
Compensation as of Fiscal Year 2014.
Intrinsic Therapeutics, Inc. Key Developments
Intrinsic Therapeutics, Inc. Presents at 12th Annual 2014 Musculoskeletal New Ventures Conference, Oct-28-2014 11:30 AM
Oct 21 14
Intrinsic Therapeutics, Inc. Presents at 12th Annual 2014 Musculoskeletal New Ventures Conference, Oct-28-2014 11:30 AM. Venue: FedEx Institute of Technology, University of Memphis, Memphis, Tennessee, United States.
Instrinsic Therapeutics Presents at Canaccord Genuity Musculoskeletal Conference, Mar-11-2014 02:50 PM
Mar 5 14
Instrinsic Therapeutics Presents at Canaccord Genuity Musculoskeletal Conference, Mar-11-2014 02:50 PM. Venue: Sheraton New Orleans Hotel, 500 Canal Street, New Orleans, Louisiana, United States.
Intrinsic Therapeutics Announces the Enrollment of the Patient in Landmark Barricaid(R) Randomized Trial
Aug 1 13
Intrinsic Therapeutics, Inc. announced the enrollment of the 400(th) patient in a level 1, prospective, randomized, multi-center clinical trial evaluating the effectiveness of its Barricaid Prosthesis in improving outcomes for lumbar discectomy patients suffering from sciatica. The surgery was performed by Dr. Frederic Martens in Aalst, Belgium. The study is being conducted in Germany, Switzerland, Austria, and The Benelux with the goal of demonstrating fewer disc reherniations and improved function in high-risk patients treated with the Barricaid compared to limited discectomy only. In addition to studying the safety and effectiveness of the Barricaid device, the information gathered from the trial will allow correlation analyses of a multitude of clinical variables that have never before been possible. The project investigates both clinical and radiographic information related to disc degeneration by studying effects of age, smoking status, BMI, musculoskeletal health, and dozens of other potential contributors to chronic low back pain. This study incorporates the key economic impact factors of discectomy failures and will measure the potential for the Barricaid to reduce overall costs.
Similar Private Companies By Industry
Recent Private Companies Transactions
August 22, 2014